絞り込み

16643

広告

A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma.

著者 Hahn AW , Drake C , Denmeade SR , Zakharia Y , Maughan BL , Kennedy E , Link C , Vahanian N , Hammers H , Agarwal N
Oncologist.2019 Sep 06 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (8view , 0users)

Full Text Sources

Miscellaneous

HyperAcute Renal immunotherapy was well tolerated and demonstrated antitumor activity in patients requiring salvage-line treatment for metastatic renal cell carcinoma (mRCC).HyperAcute Renal immunotherapy was safely administered with concomitant salvage-line treatments for mRCC, and it may be a candidate for inclusion in novel combinations for salvage treatment of mRCC because of its unique mechanism of action.
PMID: 31492769 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード